Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of AHB-137 combined with hepatitis B vaccine or peginterferon alfa-2b in HBeAg-negative chronic hepatitis B after nucleos(t)ide analogue therapy
CTR20251866Phase 2Active
- Sponsor
- HaoBo Medicine
- Start
- Jun 2025
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of AHB-137 in Chronic Hepatitis B (CHB), sponsored by HaoBo Medicine. Started Jun 2025; status: active.
02
Drugs
AHB-137
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20251866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251866.